Dropper with aminophylline: what is it used for and what are the instructions?

In what cases is a drip with aminophylline prescribed?

Parenteral administration of aminophylline is indicated in the following cases:

Relief of status asthmaticus, reversible bronchospasms of various etiologies, pulmonary emphysema;
Pulmonary hypertension, as a component of complex therapy for “emphysematous heart”;
Combinations of cardiac asthma and bronchospasm, respiratory disorders of central origin;
Relief of cerebral vegetative-vascular crises against the background of atherosclerosis of cerebral vessels;
In the treatment of cerebral blood flow insufficiency, cerebral edema, osteochondrosis of the cervical spine;
Intensive therapy of ischemic stroke.

Contraindications to the use of aminophylline:

Acute cardiovascular failure;
Angina pectoris, acute coronary syndrome;
Severe disturbances of rhythm and intracardiac conduction;
Hemorrhagic stroke, intracerebral hemorrhage;
Pulmonary edema;
Peptic ulcer of the stomach and duodenum in the acute stage;
Epilepsy, convulsive syndrome;
Hormonal pathology of the thyroid gland;
Multiple organ failure;
Pregnancy and breastfeeding.

Similar drugs:

Omnitus Syrup
Berodual Solution for inhalation
Tavipek Capsule
Pertussinum Oral solution
Ventolin Aerosol for inhalation
Euphyllin Solution for intramuscular administration
Seretide Aerosol
Fenoterol Oral tablets
Spiriva Inhalation solution
Salbutamol Aerosol

** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use the drug Eufillin, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.

Are you interested in the drug Eufillin? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Eufillin is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!

If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.

Technique, solution components and frequency of procedure

Eufillin is administered exclusively intravenously under the supervision of medical personnel!

Instructions for using aminophylline for droppers require the following certain rules:

The solution temperature should be 370C;
If possible, administer in the first half of the day (the drug has a stimulating effect on the central nervous system);
Aminophylline should be diluted only in 0.9% sodium chloride solution;
It is prohibited to mix the drug in one syringe for bolus administration.

Prepare the solution immediately before administration. Storage of residues and reuse is unacceptable.

When injecting aminophylline, the patient should be in a supine position. It is necessary to monitor blood pressure, heart rate, breathing parameters and the general subjective state of the patient. In case of rapid administration, increased heart rate, nausea, and vertigo may occur.

Asthmatic status. In case of a serious condition of the patient, it is permissible to administer aminophylline intravenously as a bolus for 5 minutes under blood pressure control with a transition to intravenous drip administration. Dilute 15 ml of aminophylline solution 2.4% in 200 ml. saline solution, add 90-120 mg of prednisolone and administer at a rate of 30-50 drops per minute. When the patient’s condition normalizes, they are transferred to alternative forms of the drug.

Pulmonary hypertension. Dilute 10-15 ml of 2.4% aminophylline in 150 ml of saline solution. Inject at a rate of 30-40 drops per minute. The saturation dose is 3 mg/kg/day. When systemic pressure decreases, they switch to tablet forms of methylxanthines.

Cerebral vascular crisis. The administration of aminophylline is combined with papaverine 2-4 ml, beta blockers (anaprilin 0.25% diluted in 500 ml. 5% glucose).

Ischemic stroke and cerebral edema. 10 ml of a 2.4% solution of aminophylline in 150 ml of saline in combination with dexamethasone, 2.0-4.0 ml of Lasix, 10 ml are administered intravenously. 25% magnesia. Additionally, L-lysine aescinate is administered 5-10 ml per 100 ml of saline solution slowly by drip. This treatment is carried out until clinical improvement.

Osteochondrosis. During periods of exacerbation, it is advisable to prescribe combined droppers with aminophylline, painkillers (analgin, baralgin), dexamethasone, Lasix, papaverine. The course of treatment lasts no longer than 7-10 days.

If possible, you need to monitor the level of potassium and theophylline in the blood serum, and do not exceed a daily dose of 10 mg/kg.

During treatment with aminophylline, you should refrain from drinking alcohol and products containing methylxanthine (coffee, cocoa, chocolate, tea).

Eufillin price

The price of Eufillin tablets (150 mg No. 30) in Russian pharmacies is 10-12 rubles, a 2.4% solution in 5 ml ampoules (package No. 10) can be bought for 35 rubles, in 10 ml ampoules (package No. 10) - for 40 rubles

In Ukraine, the cost of tablets is from 13 UAH, the price of Eufillin ampoules is from 21 UAH.

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine
Online pharmacies in KazakhstanKazakhstan

ZdravCity

Eufillin solution intravenously.
24mg/ml amp. 5ml No. 10 JSC Dalkhimfarm 48 rub. order
Eufillin tablets 150 mg 30 pcs. Pharmstandard-Leksredstva OJSC
35 rub. order

Pharmacy Dialogue

Eufillin (tab. 150 mg No. 30 (bl.)) FS.-Leksredstva
40 rub. order
Eufillin (amp. 2.4% 10ml No. 10)Novosibkhimpharm OJSC
102 RUR order
Eufillin (tab. 150 mg No. 30 (bl.)) Usolye-Sibirsky Chemical Physics Complex
33 rub. order
Eufillin (tab. 150 mg No. 30 (bl.)) BZMP
21 rub. order
Eufillin (amp. 2.4% 5ml No. 10) DHF JSC
52 RUR order

Pharmacy24

Eufillin-pharm 0.4 g No. 30 capsules TOV VTF "Farmakom", Ukraine
23 UAH. order
Eufillin-N 200 2% 5 ml No. 10 solution PAT "Farmak", Ukraine
22 UAH order
Eufillin-Darnitsa 2% 5 ml No. 10 solution
30 UAH order
Eufillin-pharm 0.25 g No. 40 tablets TOV VTF "Farmakom", Ukraine
17 UAH order
Eufillin-pharm 0.25 g No. 80 tablets TOV VTF "Farmakom", Ukraine
31 UAH order

PaniPharmacy

Eufillin ampoule Eufillin 200 solution d/in. 2% amp. 5ml No. 10 Ukraine, Darnitsa ChAO
33 UAH order
Eufillin ampoule Eufillin solution d/in. 2% amp. 5ml No. 10 Ukraine, Health LLC
30 UAH order
Eufillin-pharm tablets 0.25g N40 Ukraine, Farmakom PTF LLC
17 UAH order
Read also: Dosage of "Analgin" with "Diphenhydramine" for a child - instructions for use and reviews
Eufillin-pharm tablets 0.25g N80 Ukraine, Farmakom PTF LLC
30 UAH order
Eufillin-pharm capsules 0.4g No. 30 Ukraine, Farmakom PTF LLC
24 UAH order

What effect is expected from taking a dropper?

Effects of parenteral aminophylline:

Relieves obstruction in patients with bronchial asthma, emphysema;
Optimizes the functions of the respiratory and intercostal muscles;
Improves respiratory function parameters, blood oxygen saturation, stimulates the respiratory center;
Balances blood rheological parameters, inhibits platelet aggregation;
Stimulates the activity of the central nervous system, cardiac contractility, increases coronary blood flow;
Relieves the tone of the walls of blood vessels;
Reduces perifocal cerebral edema, intracranial pressure;
Reduces the general resistance of the arteries of the pulmonary circulation;
Increases renal perfusion, moderately stimulates diuresis;
Improves microcirculation in cartilage tissue, relieves inflammatory swelling.

It is worth remembering the likelihood of side effects:

Vertigo, migraine, psychomotor agitation, sleep disorder, tremor, convulsive syndrome, insomnia, hallucinations;
Epigastric discomfort, nausea, gastroesophageal reflux, heartburn, exacerbation of stomach ulcers, diarrhea, anorexia;
Metabolic imbalance, disturbance of the acid-base state of the blood;
Rhythm disturbances, tachycardia, vascular collapse, exacerbation of angina pectoris, extrasystoles, progression of heart failure;
Hyperthermia, facial redness, sweating, shortness of breath.

Solution for intravenous administration Euphyllin

Instructions for medical use of the drug

Description of pharmacological action

Bronchodilator, PDE inhibitor. It is the ethylenediamine salt of theophylline (which facilitates solubility and increases absorption). It has a bronchodilator effect, apparently due to a direct relaxing effect on the smooth muscles of the respiratory tract and blood vessels of the lungs. It is believed that this effect is caused by selective inhibition of the activity of specific PDEs, which leads to an increase in the intracellular concentration of cAMP. The results of in vitro experimental studies show that the main role appears to be played by type III and IV isoenzymes. Suppression of the activity of these isoenzymes may also cause some side effects of aminophylline (theophylline), including. vomiting, arterial hypotension and tachycardia. Blocks adenosine (purine) receptors, which may be one of the factors affecting the bronchi. Reduces airway hyperresponsiveness associated with the late phase response caused by inhaled allergens through an unknown mechanism that is not due to PDE inhibition or blockade of adenosine. There are reports that aminophylline increases the number and activity of T-suppressor cells in peripheral blood. Increases mucociliary clearance, stimulates contraction of the diaphragm, improves the function of the respiratory and intercostal muscles, stimulates the respiratory center, increases its sensitivity to carbon dioxide and improves alveolar ventilation, which ultimately leads to a decrease in the severity and frequency of apnea episodes. By normalizing respiratory function, it helps saturate the blood with oxygen and reduce the concentration of carbon dioxide. Strengthens ventilation of the lungs in conditions of hypokalemia. It has a stimulating effect on the activity of the heart, increases strength and heart rate, increases coronary blood flow and increases the myocardial oxygen demand. Reduces the tone of blood vessels (mainly those of the brain, skin and kidneys). It has a peripheral venodilating effect, reduces pulmonary vascular resistance, and lowers pressure in the pulmonary circulation. Increases renal blood flow and has a moderate diuretic effect. Expands extrahepatic bile ducts. Stabilizes mast cell membranes, inhibits the release of mediators of allergic reactions. Inhibits platelet aggregation (suppresses platelet activating factor and PgE2α), increases the resistance of red blood cells to deformation (improves the rheological properties of blood), reduces thrombus formation and normalizes microcirculation. It has a tocolytic effect, increases the acidity of gastric juice. In high doses it has an epileptogenic effect.

Indications for use

For parenteral use: status asthmaticus (additional therapy), neonatal apnea, ischemic cerebrovascular accident (as part of combination therapy), left ventricular failure with bronchospasm and Cheyne-Stokes type breathing disorder, edematous syndrome of renal origin (as part of complex therapy) ; acute and chronic heart failure (as part of combination therapy). For oral administration: broncho-obstructive syndrome of various origins (including bronchial asthma, COPD, including emphysema, chronic obstructive bronchitis), hypertension in the pulmonary circulation, cor pulmonale, sleep apnea; acute and chronic heart failure (as part of combination therapy).

Release form

solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration; ampoule 10 ml, box (box) 5; EAN code: 4602672000041; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packing 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour pack 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 30; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 30; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour pack 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour pack 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour pack 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour cell packaging 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour cell packaging 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour cell packaging 10, cardboard box (box) 30; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour pack 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour cell packaging 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour cell packaging 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour cell packaging 10, cardboard box (box) 30; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour plastic packaging (pallets) 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; No. P N013516/01, 2009-05-18 from Borisov Medical Preparations Plant (Republic of Belarus) Eufillin solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, cardboard pack, covered with a parcel post 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour cell packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packing 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour pack 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour packaging 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packaging 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packaging 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour packaging 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 1; solution for intravenous administration 24 mg/ml; 10 ml ampoule with ampoule knife, contour plastic packaging (pallets) 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour packaging 10, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; 5 ml ampoule with ampoule knife, cardboard pack with cardboard insert for fixing ampoules 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack with cardboard insert for fixing ampoules 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, contour pack 5, cardboard pack 2; solution for intravenous administration 24 mg/ml; ampoule 10 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard pack 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml with ampoule knife, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 5 ml, contour plastic packaging (pallets) 10, cardboard box (box) 30; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard pack 1; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 10; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 20; solution for intravenous administration 24 mg/ml; ampoule 10 ml, contour plastic packaging (pallets) 10, cardboard box (box) 30; Composition: 1 ampoule with 5 or 10 ml of solution for injection contains 0.12 or 0.24 g of aminophylline; in a cardboard box 10 pcs.

Pharmacodynamics

Pharmacokinetics

In the body, aminophylline is metabolized at physiological pH values to release free theophylline. Bronchodilating properties appear at plasma theophylline concentrations of 10-20 mcg/ml. Concentrations above 20 mg/ml are toxic. The stimulating effect on the respiratory center is realized at a lower concentration - 5-10 mcg/ml. Theophylline binding to plasma proteins is approximately 40%; in newborns, as well as in adults with diseases, binding decreases. Plasma protein binding in adults is about 60%, in newborns - 36%, in patients with liver cirrhosis - 36%. Penetrates the placental barrier (the concentration in the fetal blood serum is slightly higher than in the maternal serum). Excreted in breast milk. Theophylline is metabolized in the liver with the participation of several cytochrome P450 isoenzymes, the most important of which is CYP1A2. During metabolism, 1,3-dimethyluric acid, 1-methyluric acid and 3-methylxanthine are formed. These metabolites are excreted in the urine. 10% is excreted unchanged in adults. In newborns, a significant part is excreted in the form of caffeine (due to the immaturity of the pathways for its further metabolism), unchanged - 50%. Significant individual differences in the rate of hepatic metabolism of theophylline are the cause of pronounced variability in clearance values, plasma concentrations, and half-life. Hepatic metabolism is influenced by factors such as age, addiction to tobacco smoking, diet, diseases, and concurrent drug therapy. T1/2 of theophylline in non-smoking patients with bronchial asthma practically without pathological changes in other organs and systems is 6-12 hours, in smokers - 4-5 hours, in children - 1-5 hours, in newborns and premature babies - 10- 45 hours T1/2 of theophylline increases in the elderly and in patients with heart failure or liver disease. Clearance decreases with heart failure, liver dysfunction, chronic alcoholism, pulmonary edema, chronic obstructive pulmonary disease. Ethylenediamine does not affect the pharmacokinetics of theophylline.

Use during pregnancy

Theophylline penetrates the placental barrier. The use of aminophylline during pregnancy may result in potentially dangerous concentrations of theophylline and caffeine in the blood plasma of the newborn. Newborns whose mothers received aminophylline during pregnancy (especially in the third trimester) require medical supervision to monitor possible symptoms of theophylline intoxication. Theophylline is excreted in breast milk. When using aminophylline in a nursing mother during lactation, irritability may occur in the child. Thus, the use of aminophylline during pregnancy and lactation (breastfeeding) is possible in cases where the expected benefit of therapy for the mother outweighs the potential risk for the fetus or child.

Contraindications for use

Severe arterial hyper- or hypotension, tachyarrhythmias, peptic ulcer of the stomach and duodenum in the acute phase, hyperacid gastritis, severe dysfunction of the liver and/or kidneys, epilepsy, hemorrhagic stroke, hemorrhage in the retina, simultaneous use with ephedrine in children, childhood (up to 3 years, for prolonged oral forms - up to 12 years), hypersensitivity to aminophylline and theophylline.

Side effects

From the side of the central nervous system: dizziness, sleep disturbances, anxiety, tremor, convulsions. From the cardiovascular system: palpitations, heart rhythm disturbances; with rapid intravenous administration - the appearance of pain in the heart, decreased blood pressure, tachycardia (including in the fetus when taken in the third trimester of pregnancy), arrhythmias, decreased blood pressure, cardialgia, increased frequency of angina attacks. From the digestive system: nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea; with prolonged ingestion - anorexia. From the urinary system: albuminuria, hematuria. Allergic reactions: skin rash, itching, fever. Metabolic disorders: rarely - hypoglycemia. Local reactions: compaction, hyperemia, pain at the injection site; when used rectally, irritation of the rectal mucosa, proctitis. Other: chest pain, tachypnea, flushing, albuminuria, hematuria, hypoglycemia, increased diuresis, increased sweating.

Directions for use and doses

IV slowly (previously diluted in 10–20 ml of isotonic sodium chloride solution), i.m. 0.12–0.24 g 3 times a day for 2 weeks; children IV - 2-3 mg/kg.

Interactions with other drugs

When used simultaneously with sympathomimetics, a mutual enhancement of action occurs; with beta-blockers and lithium preparations - the effect is mutually reduced. The intensity of action of aminophylline may decrease (due to an increase in its clearance) when used simultaneously with phenobarbital, rifampicin, isoniazid, carbamazepine, sulfinpyrazone, phenytoin, as well as in smokers. The intensity of action of aminophylline may increase (due to a decrease in its clearance) when used simultaneously with macrolide antibiotics, lincomycin, quinolones, allopurinol, beta-blockers, cimetidine, disulfiram, fluvoxamine, hormonal contraceptives for oral administration, isoprenaline, viloxazine and when vaccinated against flu Xanthine derivatives may potentiate hypokalemia caused by the action of β2-adrenergic receptor stimulants, corticosteroids and diuretics. Antidiarrheal drugs and enterosorbents reduce the absorption of aminophylline. Pharmaceutically incompatible with acid solutions.

Precautions for use

IV administration should be carried out under careful monitoring of blood circulation, respiration and the general condition of the patient (heart rate, blood pressure, number of respirations).

Special instructions for use

Use with caution in severe coronary insufficiency (acute phase of myocardial infarction, angina pectoris), widespread atherosclerosis, hypertrophic obstructive cardiomyopathy, frequent ventricular extrasystoles, increased convulsive readiness, liver and/or renal failure, gastric and duodenal ulcers (history), with recent bleeding from the gastrointestinal tract, uncontrolled hypothyroidism (possibility of cumulation) or thyrotoxicosis, with prolonged hyperthermia, gastroesophageal reflux, prostatic hypertrophy, in elderly patients, in children (especially orally). Correction of the aminophylline dosage regimen may be required for heart failure, liver dysfunction, chronic alcoholism, fever, and acute respiratory infections. In elderly patients, a dose reduction may be required. When replacing the used dosage form of aminophylline with another, clinical observation and monitoring of the concentration of theophylline in the blood plasma is necessary. Aminophylline is not used simultaneously with other xanthine derivatives. During the treatment period, you should avoid eating foods containing xanthine derivatives (strong coffee, tea). Use with caution simultaneously with anticoagulants, with other theophylline or purine derivatives. Concomitant use with beta-blockers should be avoided. Aminophylline should not be used simultaneously with glucose solution. Do not use rectally in children.

Storage conditions

List B.: In a place protected from light, in a well-closed container.

Best before date

36 months